First-year medicare part D prescription drug benefits: Medication access and continuity among dual eligible psychiatric patients

Journal of Clinical Psychiatry

Volumn 71, Issue 4, 2010, Pages 400-410

  West, Joyce C ^a   Wilk, Joshua E ^a,d   Rae, Donald S ^a   Muszynski, Irvin L ^a   Rubio Stipec, Maritza ^a   Alter, Carol L ^b   Sanders, Karen E ^a   Crystal, Stephen ^c   Regier, Darrel A ^a  

^a AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; MEDICARE; MENTAL PATIENT; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; CONTINUITY OF PATIENT CARE; DIAGNOSIS-RELATED GROUPS; DRUG COSTS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICAID; MEDICARE; MEDICARE PART D; MEDICATION THERAPY MANAGEMENT; MENTAL DISORDERS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PSYCHIATRY; PSYCHOTROPIC DRUGS; QUESTIONNAIRES; UNITED STATES;

EID: 77951045951     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04608whi     Document Type: Article

References (41)

1. The Henry J. Kaiser Family Foundation. Kaiser Health Poll Report Survey: Seniors' Early Experiences With Their New Medicare Drug Plans-June 2006. http://www.kff.org/kaiserpolls/pomr072706pkg.cfm. Accessed February 25, 2008.
2. Smith V, Gifford K, Kramer S, et al. The Transition of Dual Eligibles to Medicare Part D Prescription Drug Coverage: State Actions During Implementation. Report No. 7467. Washington, DC: Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured; 2006.
3. Centers for Medicare and Medicaid Services. Overview of the Many Steps that CMS Has Taken to Make Sure All Dual Eligibles Have Medicare Prescription Drug Coverage January 1, 2006. http://www.cms.hhs.gov/States/Downloads/ AutoEnrollmentOverview.pdf. Accessed February 25, 2008.
4. Bruen BK, Miller LM. Changes in Medicaid prescription volume and use in the wake of Medicare Part D implementation. Health Aff (Millwood). 2008;27(1):196-202.
5. Kasper J, Elias R, Lyons B. Dual Eligibles: Medicaid's Role in Filling Medicare's Gaps. Washington, DC: Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured; 2004.
6. Morden NE, Garrison LP. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Aff (Millwood). 2006;25(2):491-500.
7. Stuart B, Simoni-Wastila L, Chauncey D. Assessing the impact of coverage gaps in the Medicare Part D drug benefit. Health Aff (Millwood). 2005;(suppl Web Exclusives):W5-167-W5-179.
8. Buchsbaum L, Varon J, Kagel E, et al. Perspectives on Medicare Part D and Dual Eligibles: Key Informants' Views From Three States. Washington, DC: Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured; 2007.
9. Neuman P, Strollo MK, Guterman S, et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff (Millwood). 2007;26(5):w630-w643 Epub 2007 Aug 21.
10. West JC, Wilk JE, Muszynski IL, et al. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. Am J Psychiatry. 2007;164(5):789-796.
11. Milliman Employee Benefits Client Action Bulletin (CAB-08-20R). Mental Health Parity, Other Health-Related Requirements Enacted. October 13, 2008. http://www.milliman.com/expertise/employeebenefits/publications/cab/pdfs/ CAB10-07-08R-Mental-Health-Parity.pdf. Accessed December 10, 2008.
12. Regier DA, Bufka LF, Whitaker T, et al. Parity and the use of out-ofnetwork mental health benefits in the FEHB program. Health Aff. 2008;27(1):w70-w83. (Pubitemid 351198630)
13. Centers for Medicare and Medicaid Services. Medication Therapy Management and Quality Improvement Program. In: Pub 100-18 Medicare Prescription Drug Benefit Manual. September 5, 2008. http://www.cms.hhs.gov/ PrescriptionDrugCovContra/Downloads/R3PDBv2.pdf. Accessed December 5, 2008.
14. Centers for Medicare and Medicaid Services. Why Is CMS Requiring "All or Substantially All" of the Drugs in the Antidepressant, Antipsychotic, Anticonvulsant, Anticancer, Immunosuppressant and HIV/AIDS Categories? http://www.cms.hhs.gov/PrescriptionDrugCovContra/Downloads/ FormularyGuidanceAllorSubAll.pdf. Accessed February 13, 2008.
15. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805-811.
16. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-2095.
17. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. (Pubitemid 29125132)
18. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159(10):1653-1664.
19. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8)630-639.
20. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699.
21. Huskamp HA, Stevenson DG, Donohue JM, et al. Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatr Serv. 2007;58(3):308-310. (Pubitemid 46480045)
22. Donohue JM, Frank RG. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders. Psychiatr Serv. 2007;58(10):1285-1291.
23. Medicare Payment Advisory Commission. Report to the Congress: Increasing the Value of Medicare. Washington, DC: Medicare Payment Advisory Commission; 2006.
24. Wilk JE, West JC, Rae DS, et al. Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients. Psychiatr Serv. 2008;59(1):34-39.
25. Tse G, Thompson D, Procyshyn RM. Generic clozapine: a cost-saving alternative to brand name clozapine? Pharmacoeconomics. 2003;21(1):1-11. (Pubitemid 36078489)
26. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry. 2001;62(suppl):14-17 [discussion 23-24].
27. American Psychiatric Association Steering Committee on Practice Guidelines, eds. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Compendium 2002. Washington, DC: American Psychiatric Publishing; 2002.
28. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23(1):135-146.
29. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3): w185-w195. (Pubitemid 351770278)
30. Drake RJ, Pickles A, Bentall RP, et al. The evolution of insight, paranoia, and depression during early schizophrenia. Psychol Med. 2004;34(2):285-292. (Pubitemid 38239636)
31. Opler LA, Caton CL, Shrout P, et al. Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis. 1994;182(3):174-178.
32. Swanson JW, Swartz MS, Borm R, et al. Involuntary out-patient commitment and reduction of violent behavior in persons with severe mental illness. Br J Psychiatry. 2000;176:324-331. (Pubitemid 30204657)
33. Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff (Millwood). 2007;26(3):750-760.
34. West JC, Wilk JE, Olfson M, et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56(3):283-291. (Pubitemid 40333560)
35. West JC, Duffy F, Wilk JE, et al. Patterns and quality of treatment for patients with major depressive disorder in routine psychiatric practice. Focus. 2005;3:43-50.
36. Wang PS, Simon GE, Avorn J, et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA. 2007;298(12):1401- 1411. (Pubitemid 47481606)
37. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)
38. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-429. (Pubitemid 32097260)
39. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Medicare prescription drug benefit: final rule. Fed Regist. 2005;70(18):4194-4585.
40. Centers for Medicare and Medicaid Services. 2008 PDP Landscape Source Data (v09.25.07). http://www.cms.hhs.gov/PrescriptionDrugCovGenin/. Accessed April 25, 2008.
41. Hoadley J, Hargrave E, Merrell K, et al. Medicare Part D 2008 Data Spotlight: Utilization Management. Washington, DC: Kaiser Family Foundation; 2008.